About the study
Disease target: Idiopathic Pulmonary Fibrosis (IPF)
Recruitment target: 47 participants
Duration: Minimum of 52 weeks up to 156 weeks
Study locations
NSW
- Westmead Hospital
- Royal Prince Alfred Hospital
QLD
- Gallipoli Medical Research
- Prince Charles Hospital
- Mater Misericordiae Limited
VIC
- Peninsula Health
- Box Hill Hospital
WA
- Fiona Stanley Hospital
- Institute for Respiratory Health
SA
- Royal Adelaide Hospital
What is involved?
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Primary Outcome Measure in Cohort 2
Change in lung function (measured in absolute forced vital capacity (FVC)) from baseline at week 52.
Key Secondary Outcome Measures in Cohort 2
Disease progression measured by the time to first disease progression event up to approximately 3 years.
Change from baseline score of patient questionnaire, Living with Pulmonary Fibrosis (patient reported outcomes) (at week 52 and up to approximately 3 years).
Change from baseline in walking distance measured in 6-minute walk test (6MWT) (At week 52).
Investigational medicinal product, comparator and randomisation
Active / oral; Matching placebo / oral; 1:1:1
Can I participate?
Inclusion Criteria
- ≥ 40 years of age
- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening
Exclusion Criteria
- Interstitial Lung Disease (ILD) associated with known primary causes (e.g., hypersensitivity pneumonitis, autoimmune associated ILD, sarcoidosis, etc.).
- Acute exacerbation of pulmonary fibrosis within 4 weeks prior to or during screening
- History of lung reduction surgery or lung transplant (being on transplantation list is allowed).
- ALOFT-IPF Trial Summary ALOFT-IPF-v.1-22Mar25.pdf
For further information or if you would like to take part in this research study, please complete our Patient Trial Enquiry Form or email enquiries@pactnetwork.com.au.
This study is sponsored by Bristol-Myers Squibb Company.